Top Page
Fennec Pharmaceuticals
(TSX:FRX)
Fennec Pharmaceuticals (FRX) vs. iShares MSCI Canada ETF (EWC)
Fennec Pharmaceuticals Business Overview & Revenue Model
Fennec Pharmaceuticals Earnings Call Summary
Fennec Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.79M | 47.54M | 21.25M | 1.53M | 0.00 | 170.00K |
| Gross Profit | 36.12M | 44.35M | 19.99M | 1.45M | 0.00 | 170.00K |
| EBITDA | -3.71M | 4.80M | -12.65M | -22.74M | -17.18M | -17.98M |
| Net Income | -6.94M | -436.00K | -16.05M | -23.86M | -17.46M | -18.11M |
Balance Sheet | ||||||
| Total Assets | 49.21M | 44.95M | 26.86M | 26.94M | 22.41M | 31.42M |
| Cash, Cash Equivalents and Short-Term Investments | 21.93M | 26.63M | 13.27M | 23.77M | 21.10M | 30.34M |
| Total Debt | 18.09M | 19.34M | 30.95M | 24.90M | 4.99M | 0.00 |
| Total Liabilities | 53.70M | 50.82M | 38.49M | 29.51M | 6.64M | 2.35M |
| Stockholders Equity | -4.49M | -5.87M | -11.62M | -2.57M | 15.77M | 29.07M |
Cash Flow | ||||||
| Free Cash Flow | -7.99M | 26.98M | -17.14M | -18.06M | -14.22M | -15.60M |
| Operating Cash Flow | -7.99M | 26.98M | -17.14M | -18.06M | -14.22M | -15.60M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | -10.39M | -13.62M | 6.64M | 20.73M | 4.98M | 32.29M |
Fennec Pharmaceuticals Technical Analysis
Fennec Pharmaceuticals Risk Analysis
Fennec Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | C$468.81M | -15.49 | -790.82% | ― | ― | 2.22% | |
52 Neutral | C$172.61M | -27.57 | -66.34% | ― | ― | 59.00% | |
52 Neutral | C$601.22M | -9.34 | -59.46% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $350.28M | -30.88 | ― | ― | -19.08% | -451.99% | |
46 Neutral | $226.32M | -6.88 | -89.10% | ― | ― | 27.53% |
Fennec Pharmaceuticals Corporate Events
Southpoint Capital Advisors LP has reduced its stake in Fennec Pharmaceuticals Inc., selling 1 million common shares at USD$7.50 each, a block representing about 2.93% of Fennec’s fully diluted outstanding shares. Following the transaction, Southpoint now controls roughly 2.7 million common shares, or about 8% of Fennec’s fully diluted share base, and indicated that its holdings may continue to change over time based on market conditions and other factors, signaling potential ongoing institutional trading activity in the stock.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Fennec Pharmaceuticals announced an investigator-sponsored trial by City of Hope to evaluate PEDMARK® for preventing hearing loss in adult men with metastatic testicular germ cell tumors undergoing cisplatin-based chemotherapy. This study highlights the increasing clinical interest in mitigating the long-term quality-of-life impacts of chemotherapy-induced hearing loss, potentially expanding the use of PEDMARK® into metastatic disease contexts.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Fennec Pharmaceuticals announced positive results from a Phase 2/3 clinical trial in Japan, demonstrating that PEDMARK® significantly reduces cisplatin-induced hearing loss in pediatric and adolescent patients without affecting the drug’s antitumor efficacy. With a high tumor response rate and no adverse interactions observed, the company plans to pursue registration in Japan and explore partnering opportunities, potentially enhancing its market presence and offering a solution to a significant unmet medical need.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Fennec Pharmaceuticals has successfully completed the full redemption of its outstanding convertible notes issued to Petrichor Opportunities Fund, using proceeds from a recent public offering and private placement. This move leaves the company with no outstanding debt, potentially strengthening its financial position and operational flexibility. The redemption involved a total payment of over $21 million, covering principal, accrued interest, and a redemption fee. This strategic financial maneuver could enhance Fennec’s market positioning and stakeholder confidence.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Fennec Pharmaceuticals announced the successful closing of a non-brokered private offering of common shares in Canada, raising approximately US$5,025,000. This move is part of their strategy to strengthen their financial position and support the commercialization of their flagship product, PEDMARK®. The offering was conducted under specific Canadian securities exemptions, allowing the shares to be free from a hold period, thus enhancing liquidity. This development is expected to bolster Fennec’s market presence and operational capabilities, potentially benefiting stakeholders by increasing the company’s resources for further growth and expansion.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Fennec Pharmaceuticals announced the pricing of its public offering of 4,666,667 common shares at $7.50 per share, expecting to raise approximately $35 million. The proceeds will be used to repurchase and redeem certain indebtedness and for general corporate purposes, potentially impacting the company’s financial stability and market positioning.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Fennec Pharmaceuticals announced a non-brokered private offering of its common shares in Canada, aiming to raise up to US$5,025,000. The offering, targeted at existing institutional shareholders, is expected to close on November 17, 2025, pending necessary approvals. This strategic move could enhance Fennec’s financial position and support its market operations, particularly in the commercialization of its flagship product, PEDMARK®, across various regions.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Fennec Pharmaceuticals reported a record-breaking third quarter in 2025, with net product sales reaching $12.5 million, marking a 79% year-over-year growth. The company achieved its first profitable quarter from operations, reflecting the success of its strategic initiatives to strengthen its commercial organization and expand PEDMARK® adoption. Preliminary results from a clinical trial in Japan are expected in the fourth quarter, which could lead to further market expansion and partnerships.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Fennec Pharmaceuticals announced a proposed public offering of its common shares, with plans to use the proceeds to repurchase and redeem certain debts and for general corporate purposes. This move is expected to impact the company’s financial strategy and market positioning, as it seeks to strengthen its capital structure and support its ongoing operations.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.